Clinical trial
Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects…
NCT00111995 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00111995 |
|---|---|
| Title | Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis |
| Official title | A Randomized, Double-Blind Study Comparing Aranesp® (Darbepoetin Alfa) and Recombinant Human Erythropoietin (rHuEPO) in the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Chronic Renal Failure, Anemia |
| Intervention type | Drug |
| Interventions | Aranesp® |
| Enrollment | 400 |
| Start date | May 1, 2002 |
| First posted | May 30, 2005 |
| Last update posted | Aug 8, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: